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Edited by Horst FeldmannAbstract The mitochondrial phospholipid cardiolipin is synthe-
sized from cytidinediphosphate-diacylglycerol and phosphatidyl-
glycerol, a process catalyzed by the enzyme cardiolipin synthase.
In this study, we identiﬁed a human candidate gene/cDNA for
cardiolipin synthase, C20orf155. Expression of this candidate
cDNA in the (cardiolipin synthase-deﬁcient) crd1D yeast con-
ﬁrmed that it indeed encodes human cardiolipin synthase. Puri-
ﬁed mitochondria of the crd1D expressing human cardiolipin
synthase were used to characterize the enzyme. It has an alkaline
pH optimum, requires divalent cations for activity and appears to
have a diﬀerent substrate preference for cytidinediphosphate-
diacylglycerol species when compared to phosphatidylglycerol
species. The possible implications for CL synthesis and remodel-
ing are discussed.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cardiolipin (CL) is an anionic phospholipid with a unique
diphosphatidylglycerol structure, containing four acyl groups
[1]. In eukaryotes, CL is predominantly found in the inner
mitochondrial membrane where it comprises approximately
16% of total phospholipids [2]. It has been shown that CL is
essential for maintaining the mitochondrial membrane poten-
tial [3], is involved in the stabilization of supercomplexes of
respiratory chain complexes III and IV [4] and is required
for the activity of several mitochondrial enzymes, e.g., the
ADP/ATP carrier [5]. More recent reports show that CL and
its metabolites are also involved in apoptosome mediated
apoptosis [6].
Synthesis of CL occurs at the inner mitochondrial
membrane by the transfer of the phosphatidyl group of
cytidinediphosphate-diacylglycerol (CDP-DAG) to phosphati-Abbreviations: At, Arabidopsis thaliana; BTP, Bis-Tris propane; CDP-
DAG, cytidinediphosphate-diacylglycerol; CL, cardiolipin; CLS, car-
diolipin synthase; Hs, Homo sapiens; PG, phosphatidylglycerol; Sc,
Saccharomyces cerevisiae
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doi:10.1016/j.febslet.2006.04.054dylgly- cerol (PG), a process catalyzed by the enzyme CL syn-
thase (CLS). This conversion of PG into CL is so eﬀective that
mitochondrial membranes only contain trace amounts of PG
[7]. CLS from rat liver [8,9], yeast [10–13], and plants [14,15]
have been characterized and the respective genes of yeast
and Arabidopsis thaliana were cloned [10,11,13,15,16]. In gen-
eral, mitochondrial CLSs have an alkaline pH optimum, re-
quire divalent cations (Co2+, Mg2+, or Mn2+) for activity
and possess distinctly lower Km values for CDP-DAG than
for PG [9]. CLS from rat liver mitochondria displays the
highest activity towards medium-chain CDP-DAGs (dilauroyl
and dimyristoyl) when compared to long-chain CDP-DAGs
(dipalmitoyl and distearoyl) and has a preference for
unsaturated long-chain CDP-DAG species (dioleoyl =
dilinoleoyl > distearoyl) but it is more active with CDP-1-
palmitoyl-2-oleoylglycerol than with CDP-dioleoylglycerol or
-dilinoleoylglycerol [8]. Hence, according to the substrate
species speciﬁcity the CLS cannot establish the typical fatty
acid pattern of CL in mammalian cells, predominantly consist-
ing of linoleic acid. This typical fatty acid composition is cre-
ated by remodeling of newly synthesized CL. It is generally
accepted that at least two CL remodeling systems exist in
mammalian cells which are involved in obtaining the observed
CL composition. CL has been shown to be remodeled by
transacylation from phosphatidylcholine and phosphatidyleth-
anolamine [17] and by deacylation/reacylation [18]. Impaired
remodeling of CL in human cells caused by a defect in the
tafazzin gene is associated with Barth syndrome, a severe ge-
netic disorder characterized by cardioskeletal myopathy, neu-
tropenia and respiratory chain defects [19–21]. In this study,
we aimed to identify and characterize the human CLS because
the substrate preference of CLS has important implications for
remodeling of de novo synthesized CL.2. Materials and methods
2.1. Cloning and expression of the human candidate CLS cDNA in
Saccharomyces cerevisiae
The putative human CLS (HsCLS) was identiﬁed by sequence
homology searches using the Swiss Institute of Bioinformatics BLAST
network service (http://www.expasy.org/) [22] employing the CLS
amino acid sequences of yeast (ScCLS or crd1 or YDL142c) and Ara-
bidopsis thaliana (AtCLS or At4g04870). The HsCLS candidate cDNA
sequence was ampliﬁed by PCR from I.M.A.G.E. clone 2011896
(ATCC, Manassas, VA), using a forward primer 5 0-GGT ACC ATG
CTA GCC TTG CGC GTG GC-3 0 containing a KpnI restriction site
and a reverse primer 5 0-GTC GAC TCA GTC TTT TAT CAC CTGblished by Elsevier B.V. All rights reserved.
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mer, 5 0-GTC GAC TCA ATGATG ATG ATG ATG ATGGTC TTT
TAT CAC CTG AAC AGT C-3 0 containing a SalI restriction site was
used to amplify the open reading frame including a 3 0-sequence encod-
ing a C-terminal 6· HIS-tag. Both PCR products were ligated into the
pGEM-T vector (Promega, Madison, WI, USA). Sequence analysis
was performed to exclude sequence errors introduced by the Taq poly-
merase, and both the tagged and untagged cDNAs were cloned into
the KpnI and SalI restriction sites of the pYPGK18 vector suitable
for constitutive expression in yeast [20]. Both constructs were trans-
formed to the crd1D (BY4742; MATalpha; his3D1; leu2D0; lys2D0;
ura3D0; YDL142c::kanMX4) and to the BY4742 wild type (BY4742;
MATalpha; his3D1; leu2D0; lys2D0; ura3D0) yeast strain using the lith-
ium acetate procedure [23]. Both yeast strains were a kind gift of Dr.
Toon de Kroon, Utrecht University. Yeast cells were grown at 28 C
on minimal glucose medium, containing 0.67% (w/v) Yeast Nitrogen
Base without amino acids (Difco Sparks, MD, USA) and 2% (w/v) glu-
cose (Sigma, St. Louis, MO, USA), containing the appropriate amino
acids required for growth.WT+pYPGK18
Dilution
101 102 103 104
crd1Δ+pYPGK18
crd1Δ+HsCLS
crd1Δ+HsCLS-HIS
Fig. 1. Complementation analysis by growth phenotype. Yeast
suspensions of wild type (WT) strain containing the empty vector
pYPGK18, crd1D + pYPGK18, crd1D + HsCLS and crd1D + HsCLS-
HIS were diluted 101, 102, 103, and 104 times, spotted on 2% glucose
plate and incubated at 37 C. Compared to wild type, crd1D clearly
shows retarded growth, which is restored by expression of either
HsCLS or HsCLS-HIS.2.2. Complementation analysis
For growth phenotype complementation analysis, transformants
were grown in minimal glucose medium and harvested in mid-expo-
nential phase. Cells were washed in phosphate-buﬀered saline and
resuspended to OD600 = 1. Subsequently, the yeast suspension was di-
luted 101, 102, 103, and 104 times, and 6 ll of each dilution was spotted
on minimal glucose plates (0.67% (w/v) Yeast Nitrogen Base without
amino acids, 2% (w/v) glucose and 2% (w/v) agar) which were placed
at 37 C.
To analyze the PG and CL content in the diﬀerent transformants,
50 ml yeast culture was harvested in mid-exponential phase and pel-
leted. Cell pellets were lyophilized overnight, after which lipids were
extracted. Ten milligrams of lyophilized yeast powder were resus-
pended in 1 ml of methanol and sonicated for 1 min at 9 W using a
tip sonicator. Two milliliters of chloroform were added followed by
sonication for 20 min in a sonicator bath. After addition of 1 ml of
demineralized water the internal standard (0.4 nmol of CL(14:0)4
(Avanti Polar Lipids, Alabaster, AL) dissolved in 50 ll chloroform)
was added to the extraction. This mixture was shaken vigorously
and placed on ice for 15 min, after which it was centrifuged at
1000 · g for 10 min. The organic layer was transferred into another
tube, and the aqueous layer was reextracted with 3 ml of 2:1 chloro-
form–methanol (v/v). The combined organic layers were evaporated
under a stream of nitrogen at 45 C. The residue was dissolved in
150 ll of chloroform/methanol/water (50:45:5 v/v/v) containing
0.01% NH4OH, and 5 ll of this solution was injected into the HPLC
MS system.
2.3. HPLC mass spectrometry
The HPLC system consisted of a Surveyor quaternary gradient
pump, a vacuum degasser, a column temperature controller and an
autosampler (Thermo Electron Corporation, Waltham, MA). The col-
umn temperature was maintained at 25 C. The lipid extract was in-
jected onto a 2.1 · 250 mm silica column, 5 lm particle diameter
(Merck, Darmstadt, Germany). The phospholipids were separated
from interfering compounds by a linear gradient between solution B
(chloroform–methanol, 97:3, v/v) and solution A (methanol–water,
85:15, v/v). Solutions A and B contained 0.1 and 0.01 ml of 25%
(v/v) aqueous ammonia per liter of eluent, respectively. The gradient
(0.3 ml/min) was as follows: 0–10 min: 20% A to 100% A; 10–12 min,
100% A; 12–12.1 min: 100% A to 0% A; and 12.1–17 min, equilibration
with 0% A. All gradient steps were linear, and the total analysis time,
including the equilibration, was 17 min. A splitter between the HPLC
column and the mass spectrometer was used, and 75 ll/min eluent was
introduced into the mass spectrometer.
A TSQ Quantum AM (Thermo Electron Corporation) was used in
the negative electrospray ionization mode. Nitrogen was used as neb-
ulizing gas. The source collision-induced dissociation collision energy
was set at 10 V. The spray voltage used was 3600 V, and the capillary
temperature was 300 C. Mass spectra of CL molecular species were
obtained by continuous scanning from m/z 400 to m/z 1000 with a scan
time of 2 s. PG molecular species were measured using a parent ion
scan (from m/z 400 to m/z 1000) for m/z 172.1 in the positive ion mode.
The respective spectra of CL and PG species were acquired duringtheir corresponding retention time in the HPLC elution proﬁle. A sum-
mation of the peak areas of the complete isotopic clusters of the diﬀer-
ent CL or PG species were divided by the peak area of the whole
isotopic cluster of the corresponding internal standard. This ratio
was used as a measure for the total amount of CL and PG. Levels
of the wild type BY4742 strain were set at 100%.
2.4. Isolation of yeast mitochondria
The crd1D yeast strain, and the crd1D expressing the putative
HsCLS were grown in 5 l ﬂasks containing 1.5 l of 2% glucose medium
at 28 C (225 rpm). Cells were harvested by centrifugation at 1900 · g
and washed with demineralized water. Spheroplasts were prepared
using the zymolyase procedure [24]. Yeast mitochondria were isolated
as described previously [25].
The ﬁnal mitochondrial pellet was resuspended in buﬀer containing
10 mM Tris-maleate, 0.6 M mannitol, and 0.5 mM phosphate, pH 6.8.
Protein quantiﬁcation of the mitochondrial fraction was performed as
described by Bradford [26]. Mitochondria were snap-frozen in liquid
nitrogen and stored at 80 C until analysis.
2.5. CLS enzyme activity measurement and HsCLS characterization
For CLS assays, isolated mitochondria were washed twice with
10 mM Bis–Tris propane-HCl (BTP) buﬀer pH 7.4, and resuspended
in this buﬀer containing 50% glycerol (about 1 mg protein/ml). One
to 6 lg of mitochondrial protein was used for CLS assays in a total
volume of 50 ll, as described before [15], but the reaction mixtures
were incubated at 37  C for 1 h.
The pH optimum was determined using 4 lMCDP-dioleoyl[U-14C]-
glycerol and 1 mM dioleoyl-PG in a reaction mixture containing
50 mM BTP-HCl buﬀer at diﬀerent pH values. PG substrate speciﬁcity
of the HsCLS was tested in reaction mixtures containing 50 mM BTP
buﬀer, pH 8.5, 4 lM CDP-dioleoyl[U-14C]-glycerol (330 dpm/pmol),
100 mM CoCl2 and increasing concentrations of diﬀerent PG species
(dioleoyl-PG, 1-palmitoyl-2-oleoyl-PG, and dipalmitoyl-PG were from
Sigma, dilinoleoyl-PG and 1-palmitoyl-2-linoleoyl-PG were from
Avanti Polar Lipids). CDP-DAG substrate selectivity was determined
by a competition experiment. To this end, CLS activity was measured
with 1 mM PG (dioleoyl species) and labeled CDP-dioleoylglycerol
(2.6 lM) in the presence of increasing concentrations of diﬀerent unla-
beled CDP-DAG species (Sigma) and the degree of inhibition in the
labeling rates of CL was used as a read-out. Reaction mixtures were
stopped and lipids were extracted with 240 ll chloroform:methanol
(1:1, v/v) containing 50 lg CL and 100 ll of 0.2 M H3PO4, 1 M KCl.
After phase separation, the chloroform layers were analyzed by thin
layer chromatography on Silica Gel 60 (Merck) plates in chloro-
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Fig. 2. Complementation analysis by CL proﬁle analysis. CL proﬁles of wild type and the crd1D mutant strain containing the empty vector
pYPGK18 (WT + pYPGK18, crd1D + pYPGK18) or a HsCLS gene construct (crd1D + HsCLS and crd1D + HsCLS-HIS) are shown in the region
from m/z 600 to m/z 720. Peaks at m/z 619.5 (CL i.s.) and m/z 665.5 (PG i.s.) represent the internal standards of CL and PG, respectively. The
abundance of the CL internal standard was set at 100% (PG i.s. is not fully depicted). When compared to the wild type yeast, CLs are clearly deﬁcient
in crd1D. Expression of either HsCLS or HsCLS-HIS completely normalizes the CL proﬁle and reduces the PG levels, which are elevated in crd1D
(arrows).
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lipids were visualized with a Bioimager FLA 3000 (Raytest, Straubing,
Germany) and quantiﬁed by scintillation counting.3. Results and discussion
3.1. Identiﬁcation of HsCLS and complementation of crd1D
To identify the HsCLS gene/cDNA, we performed BLAST
analysis using the AtCLS (At4g04870) and ScCLS (crd1 or
YDL142c) amino acid sequences and identiﬁed a (predicted)
human gene termed C20orf155. The translated putative open
reading frame showed high sequence homology with bothCLS orthologues. No other human protein displayed signiﬁ-
cant homology towards the conﬁrmed CLS sequences. The
putative HsCLS gene is localized at chromosome 20p13-
p12.3 and encodes a protein of 301 amino acids. The protein
is predicted to contain a C-terminal transmembrane segment
(http://psort.ims.u-tokyo.ac.jp) [27] and belongs to the CDP-
alcohol phosphatidyltransferase class-I family like the CLS
of other eukaryotes [10,11,13,15,16]. It contains a putative
N-terminal mitochondrial targeting sequence as predicted by
the subcellular localization program MitoProtII (http://
ihg.gsf.de/ihg/mitoprot.html) [28]. We ampliﬁed the candidate
open reading frame by PCR from I.M.A.G.E. clone 2011896
and cloned it into the pYPGK18 vector, suitable for
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Fig. 4. pH proﬁle of HsCLS. Reaction products were formed from
4 lM CDP-dioleoyl [U-14C]glycerol and 1 mM dioleoyl-PG by mito-
chondrial fractions of crd1D + HsCLS cells in 50 mM BTP-HCl buﬀer
at diﬀerent pH values.
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empty vector were transformed to the CLS-deﬁcient, and
therefore completely CL-deﬁcient, crd1D strain of S. cerevisiae.
This deletion mutant displays delayed growth at elevated tem-
peratures [29] and we used this property as a read-out to inves-
tigate whether the human candidate cDNA protein product is
functionally active as a CLS. Fig. 1 shows that expression of
the HsCLS candidate cDNA results in complete complementa-
tion of the growth phenotype, which is not observed in the
CLS-deﬁcient strain transformed with the empty vector
(pYPGK18). Like for the untagged HsCLS, expression of
the HIS-tagged HsCLS candidate protein restores growth at
elevated temperatures (Fig. 1).
To investigate whether CL levels were restored in the crd1D
expressing the HsCLS candidate cDNA, we performed CL and
PG analysis by HPLC MS in the crd1D transformed with the
putative HsCLS cDNA (with and without C-terminal HIS-
tag) and the empty vector (pYPGK18). These CL/PG spectra
were compared to the wild type CL/PG spectrum. Fig. 2 shows
that CLs are present in the transformant expressing the puta-
tive HsCLS whereas the deletion mutant transformed with the
empty vector completely lacks CL. To compensate for the lack
of CL, the crd1D strain is known to contain highly elevated
levels of PG [10]. A semiquantitative determination of the
CL and PG levels in the diﬀerent transformants is depicted
in Fig. 3. The crd1D strain contains over 35 times more PG
than the wild type strain. Expression of either HsCLS or
HsCLS-HIS almost completely reverses the accumulation of
PG, which is most likely used for CL synthesis (Fig. 3).
In order to investigate whether the HsCLS candidate protein
indeed is able to synthesize CL, we puriﬁed mitochondria from
the crd1D cells expressing the candidate HsCLS or harboring
the empty vector and used these as enzyme source for
in vitro CLS assays. Fig. 5 shows that the expression of the
putative HsCLS restores the formation of CL using CDP-diol-
eoyl [U-14C]-glycerol and dioleoyl-PG as substrates.
In conclusion, the growth phenotype complementation, the
HPLC MS analysis and the CLS activity measurements of
the diﬀerent transformants demonstrate that the C20orf155
gene indeed encodes human CLS. The HsCLS ORF has beenWT
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Fig. 3. Semiquantitative analysis of CL and PG levels. CL and PG levels o
pYPGK18 (WT + pYPGK18, crd1D + pYPGK18) or a HsCLS gene const
HPLC MS analysis. WT levels were set at 100% for both CL and PG. PG l
(n.d.). Expression of either HsCLS or HsCLS-HIS completely normalizes th
level.deposited in GenBank (accession number DQ386730). While
this manuscript was under review, Lu and colleagues con-
ﬁrmed that this ORF indeed encodes HsCLS and is highly
expressed in heart, skeletal muscle and liver [30].
3.2. Characterization of HsCLS
Since the substrate speciﬁcity of HsCLS has considerable
implications for CL remodeling previous to or after the actual
synthesis of the CL molecule, we investigated the substrate
speciﬁcity for both PG and CDP-DAG species of the recom-
binant HsCLS enzyme. First, we optimized our assay condi-
tions. Like CLS from various eukaryotes [8,15,31], the
HsCLS enzyme has an alkaline pH optimum (Fig. 4), requires
divalent cations for activity (Fig. 5) and has the highest activ-
ity in the presence of 100 mM divalent cations. Unlike the rat
liver CLS [8], the HsCLS displayed similar activities with
Co2+, Mn2+ and Mg2+ (Fig. 5). With the dioleoyl species ofcrd1Δ
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Fig. 6. PG and CDP-DAG species speciﬁcity of the HsCLS expressed
in yeast mitochondria. (A) Shows the incorporation rates of CDP-
dioleoyl[U-14C]glycerol into CL by mitochondrial fractions of
crd1D + HsCLS cells as a function of the concentration of diﬀerent
PG species. HsCLS shows a slight preference for dioleoyl-PG and
dilinoleoyl-PG, has similar activities for 1-palmitoyl-2-oleoyl-PG, 1-
palmitoyl-2-linoleoyl-PG and dipalmitoyl-PG and virtually no activity
with dimyristoyl-PG. (B) Shows the degree of inhibition in the
incorporation rates of CDP-dioleoylglycerol[U-14C]glycerol into CL
by increasing concentrations of diﬀerent unlabeled CDP-DAG species.
Competition experiments with [14C]-CDP-dioleoylglycerol show that
HsCLS has similar activity with CDP-dimyristoylglycerol, CDP-DAG
from egg yolk phosphatidylcholine (PC) and CDP-dioleoylglycerol.
CDP-dipalmitoyl shows considerably less activity.
Fig. 5. TLC analysis of in vitro CLS assay. Reaction products were
formed from CDP-dioleoyl [U-14C]glycerol and PG by mitochondrial
fractions of crd1D + pYPGK18 cells (lanes 1, 3, 5, 7) and
crd1D + HsCLS cells (lanes 2, 4, 6, 8) in the absence of divalent
cations (lanes 1 and 2) or in the presence of 100 mM Co2+ (lanes 3 and
4) or 100 mM Mg2+ (lanes 5 and 6) or 100 mM Mn2+ (lanes 7 and 8).
R.H. Houtkooper et al. / FEBS Letters 580 (2006) 3059–3064 3063both substrates, the HsCLS showed maximal activity at 1 mM
PG and 4.5 lM CDP-DAG resulting in speciﬁc enzyme activ-
ities of about 60 pmol/(min mg protein) (data not shown).
These data suggest that the HsCLS has a distinctly lower
Km value for CDP-DAG than for PG, as was reported for
CLS from other eukaryotes [9,12,14,15]. Fig. 6A shows that
HsCLS was more active with dioleoyl and dilinoleoyl species
of PG than with species with one or two palmitoyl groups as
reported for the respective enzymes from plants [14,15].
Dimyristoyl-PG was a very poor substrate for the enzyme.
The same PG species speciﬁcity as that shown in Fig. 6A
was obtained when the CoCl2 was substituted by MnCl2.
The CDP-DAG competition assays revealed that the speciﬁc-
ity of HsCLS towards CDP-DAG species diﬀered from that
towards PG species, especially with regard to dimyristoyl sub-
strate species. As depicted in Fig. 6B, CDP-dimyristoylglyc-
erol as well as the species mixture from egg lecithin
(primarily CDP-1-palmitoyl-2-oleoylglycerol) eﬃciently com-
peted with the dioleoyl species for CL synthesis, whereas
the dipalmitoyl species was distinctly less eﬀective (Fig. 6B).
Since the in vivo levels of CDP-DAG species containing med-
ium-chain fatty acids are low when compared to long-chain
fatty acids [32,33], the former are unlikely to represent the
physiological substrates of CLS and contribute to CL synthe-
sis, in spite of the preference of CLS in vitro. Of the more
physiological substrates, CDP-DAG from egg lecithin (pri-
marily CDP-1-palmitoyl-2-oleoylglycerol) and CDP-dioleoyl-
glycerol display similar activities. These data suggest that
the incorporation of such mixed species into CL cannot be
prevented by the properties of the HsCLS. In addition, the
enzyme displayed no speciﬁcity for linoleoyl containing PG
species when compared to the respective oleoyl containing
species. Hence, the observed properties of the HsCLS under-
line the importance of remodeling mechanisms following CL
synthesis in order to establish the typical fatty acid pattern
of CL. Two remodeling mechanisms have been reported that
can act upon the newly synthesized CL to obtain the speciﬁc
linoleoyl-containing CL species. Experiments from Xu and
colleagues elegantly show that diﬀerent CL species can be eﬃ-
ciently remodeled into linoleoyl-containing CL species (pre-
dominantly tetralinoleoyl- and trilinoleoyl-oleoyl-CL) in the
presence of labeled linoleoylphosphatidylcholine [17]. Ma
and colleagues identiﬁed a monolyso-CL acyltransferase
activity speciﬁc for oleoyl- and linoleoyl-CoA which isthought to be involved in the deacylation/reacylation cycle
of CL [18].
An interesting observation is that the CL species in the wild
type yeast strain are the same as those of the crd1D strain
expressing the HsCLS. This suggests that the properties of hu-
man and yeast CLSs are very similar and thus appear to be
evolutionary conserved. This is in contrast with the large dif-
ference in CL composition of yeast and that of human tissues
[34]. The high degree of linoleoyl content in human CL to-
gether with the evolutionary conserved substrate speciﬁcity
of HsCLS suggests that suitable remodeling mechanisms have
been developed as an additional system to obtain this more
unsaturated composition.
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